ACELYRIN on its $621 Million IPO
Cooley advised ACELYRIN, a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever. Lawyers Chadwick Mills, Charlie Kim and Anitha Anne led the Cooley team.
Structure Therapeutics on its $185.3 Million IPO
Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.
TI Cloud on its HK$559.4 Million IPO
Cooley advised TI Cloud, a cloud-native customer contact solution provider, on its HK$559.4 million ($71.7 million) initial public offering of 43,530,000 shares (subject to an overallotment option to issue an additional 6,529,400 shares), which now trade on the Hong Kong Stock Exchange. Partners Michael Yu and Will Cai led the […]
GOGOX on its HK$675 Million IPO
Cooley advised GOGOX, an online intracity logistics platform in Asia focused on the transportation of freight and goods in urban areas, on its HK$675 million (US$86 million) initial public offering of 3,120,000 shares (subject to an overallotment option to issue an additional 4,680,000 shares), which now trade on the Hong […]
The Clorox Company on its $1.1 Billion Unsecured Senior Notes Offering
Cooley advised the underwriters on The Clorox Company’s registered debt offering of $1.1 billion aggregate principal amount of investment grade unsecured senior notes. The offering consisted of $500 million of 4.400% senior notes due 2029 and $600 million of 4.600% senior notes due 2032. Partners Eric Blanchard and Richard Segal, […]
Huitongda Network on its HK$2.2 Billion IPO
Cooley advised the joint sponsors and underwriters on ecommerce company Huitongda’s HK$2.2 billion (US$285 million) initial public offering of 51,606,200 H shares on the Hong Kong Stock Exchange, subject to the exercise of the underwriters’ option to purchase an additional 7,740,900 H shares. Partners Michael Yu and Will Cai led […]
Ascendis Pharma on its $575 Million Convertible Notes Offering
Cooley advised the underwriters on Ascendis Pharma’s offering of $575 million aggregate principal amount of 2.25% Convertible Senior Notes due 2028. J.P. Morgan, Evercore ISI, Wells Fargo Securities, Morgan Stanley and Credit Suisse acted as joint book-running managers for the offering. Ascendis Pharma is a biopharmaceutical company. Partners Denny Won, […]
CinCor Pharma on its $212 Million IPO
Cooley advised CinCor Pharma on its upsized $212 million initial public offering of 13,290,813 shares of common stock, which included a partial exercise of the underwriter’s option to purchase additional shares of common stock. CinCor, whose shares now trade on the Nasdaq Global Market under the symbol CINC, is a […]
Confluent on its $1.1 Billion Convertible Senior Notes Offering
Cooley advised Confluent on its offering of $1.1 billion aggregate principal amount of 0.00% convertible senior notes due 2027. Confluent has pioneered a new category of data infrastructure designed to connect all the applications, systems and data layers of a company around a real-time central nervous system.
Global Blood Therapeutics on its $345 Million Convertible Senior Notes Offering
Cooley advised the initial purchasers on Global Blood Therapeutics’ Rule 144A offering of $345 million aggregate principal amount of 1.875% Convertible Senior Notes due 2028. In connection with the offering, GBT entered into capped call transactions. Goldman Sachs & Co. and Jefferies acted as joint book-running managers for the offering. […]